## Felix K Niggli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6010036/publications.pdf

Version: 2024-02-01

53660 42291 9,655 181 45 92 citations h-index g-index papers 183 183 183 12947 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	CD4Â+ÂT cells are found within endemic Burkitt lymphoma and modulate Burkitt lymphoma precursor cell viability and expression of pathogenically relevant Epstein–Barr virus genes. Cancer Immunology, Immunotherapy, 2022, 71, 1371-1392.	2.0	3
2	Long-Term Clinical Outcome and Prognostic Factors of Children and Adolescents with Localized Rhabdomyosarcoma Treated on the CWS-2002P Protocol. Cancers, 2022, 14, 899.	1.7	14
3	Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization. Neoplasia, 2022, 27, 100784.	2.3	3
4	Longâ€ŧerm results from the multicentric European randomized phase 3 trial CWS/RMSâ€96 for localized highâ€risk soft tissue sarcoma in children, adolescents, and young adults. Pediatric Blood and Cancer, 2022, 69, e29691.	0.8	11
5	CRISPR activation screen identifies $TGF\hat{l}^2$ -associated PEG10 as a crucial tumor suppressor in Ewing sarcoma. Scientific Reports, 2022, 12, .	1.6	O
6	Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group. Haematologica, 2021, 106, 1390-1400.	1.7	5
7	Support of BCP-ALL-cells by autologous bone marrow Th-cells involves induction of AID expression but not widespread AID off-target mutagenesis. Cancer Immunology, Immunotherapy, 2021, 70, 2275-2289.	2.0	3
8	Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. Cancers, 2021, 13, 2075.	1.7	23
9	Extraskeletal Ewing sarcoma in children, adolescents, and young adults. An analysis of three prospective studies of the Cooperative Weichteilsarkomstudiengruppe (CWS). Pediatric Blood and Cancer, 2021, 68, e29145.	0.8	11
10	The effect of adjuvant therapies on long-term outcome for primary resected synovial sarcoma in a series of mainly children and adolescents. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3735-3747.	1.2	3
11	Treatment of children with acute lymphoblastic leukemia in Cambodia. Pediatric Blood and Cancer, 2021, 68, e29184.	0.8	2
12	Infantile myofibromatosis: Excellent prognosis but also rare fatal progressive disease. Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. Pediatric Blood and Cancer, 2021, , e29403.	0.8	5
13	The impact of local control in the treatment of children with advanced infantile and adult-type fibrosarcoma: Experience of the cooperative weichteilsarkom studiengruppe (CWS). Journal of Pediatric Surgery, 2020, 55, 1740-1747.	0.8	16
14	Lowâ€grade fibromyxoid sarcoma: A report of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatric Blood and Cancer, 2020, 67, e28009.	0.8	8
15	Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia, 2020, 34, 1694-1700.	3.3	24
16	Endothelial cell malignancies in infants, children and adolescents: Treatment results of three Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. Pediatric Blood and Cancer, 2020, 67, e28095.	0.8	5
17	39·0°C versus 38·5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial. The Lancet Child and Adolescent Health, 2020, 4, 495-502.	2.7	11
18	Malignant peripheral nerve sheath tumors in children, adolescents, and young adults: Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. Journal of Surgical Oncology, 2020, 122, 1337-1347.	0.8	6

#	Article	IF	CITATIONS
19	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Advances, 2020, 4, 4052-4064.	2.5	5
20	Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity. Nature Communications, 2020, 11, 4629.	5.8	32
21	Dermatofibrosarcoma protuberans in children and adolescents: Primary and Relapsed disease—Experience of the Cooperative Weichteilsarkomstudiengruppe (CWS). Journal of Surgical Oncology, 2020, 122, 263-272.	0.8	6
22	Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS). Journal of Cancer Research and Clinical Oncology, 2020, 146, 953-960.	1.2	10
23	Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. European Journal of Cancer, 2019, 122, 61-71.	1.3	14
24	Desmoplastic small round cell tumors: Multimodality treatment and new risk factors. Cancer Medicine, 2019, 8, 527-542.	1.3	39
25	USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth. Scientific Reports, 2019, 9, 951.	1.6	28
26	RhabdomyosarcomaÂdiagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatric Blood and Cancer, 2019, 66, e27652.	0.8	17
27	Bone marrow T helper cells with a Th1 phenotype induce activation and proliferation of leukemic cells in precursor B acute lymphoblastic leukemia patients. Oncogene, 2019, 38, 2420-2431.	2.6	5
28	Localized synovial sarcoma of the foot or ankle: A series of 32 Cooperative Weichteilsarkom Study Group patients. Journal of Surgical Oncology, 2019, 119, 109-119.	0.8	10
29	Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol. Blood, 2019, 134, 2589-2589.	0.6	5
30	Highâ€dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survival—The Gesellschaft fÃ⅓r PÃdiatrische Onkologie und HÃmatologie (GPOH) experience. Pediatric Blood and Cancer, 2018, 65, e26746.	0.8	35
31	Palliative care in Swiss pediatric oncology settings: a retrospective analysis of medical records. Supportive Care in Cancer, 2018, 26, 2707-2715.	1.0	10
32	Inflammatory myofibroblastic tumorsâ€"A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe. Pediatric Blood and Cancer, 2018, 65, e27012.	0.8	38
33	Spatial clustering of childhood cancers in Switzerland: a nationwide study. Cancer Causes and Control, 2018, 29, 353-362.	0.8	9
34	Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma. British Journal of Haematology, 2018, 182, 735-739.	1.2	12
35	Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). Journal of Clinical Oncology, 2018, 36, 244-253.	0.8	71
36	Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG) Tj ETQq0 (19, 1061-1071.	0 0 rgBT /O 5.1	verlock 10 Tf 5 137

19, 1061-1071.

#	Article	IF	Citations
37	Alveolar softâ€part sarcoma: Primary metastatic disease and metastatic relapse occurring during longâ€term followâ€up. Pediatric Blood and Cancer, 2018, 65, e27405.	0.8	16
38	Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euroâ€EWING 99 trial. Pediatric Blood and Cancer, 2017, 64, e26524.	0.8	4
39	Spatial clustering of childhood leukaemia in Switzerland: A nationwide study. International Journal of Cancer, 2017, 141, 1324-1332.	2.3	12
40	Parents' and Physicians' Perceptions of Children's Participation in Decision-making in Paediatric Oncology: A Quantitative Study. Journal of Bioethical Inquiry, 2017, 14, 555-565.	0.9	13
41	Space-Time Clustering of Childhood Leukemia: Evidence of an Association with ETV6-RUNX1 (TEL-AML1) Fusion. PLoS ONE, 2017, 12, e0170020.	1.1	7
42	Ewing's Sarcoma as a Second Malignancy in Long-Term Survivors of Childhood Hematologic Malignancies. Sarcoma, 2016, 2016, 1-11.	0.7	15
43	Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer. European Journal of Cancer, 2016, 64, 101-106.	1.3	15
44	Socioeconomic disparities in childhood cancer survival in <scp>S</scp> witzerland. International Journal of Cancer, 2016, 138, 2856-2866.	2.3	39
45	Primary Metastatic Synovial Sarcoma: Experience of the CWS Study Group. Pediatric Blood and Cancer, 2016, 63, 1198-1206.	0.8	37
46	Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica, 2016, 101, 1581-1591.	1.7	58
47	Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood, 2016, 127, 2101-2112.	0.6	208
48	Putting patient participation into practice in pediatricsâ€"results from a qualitative study in pediatric oncology. European Journal of Pediatrics, 2016, 175, 1147-1155.	1.3	32
49	Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue. Journal of Biological Chemistry, 2016, 291, 26922-26933.	1.6	23
50	Temporal association between childhood leukaemia and population growth in Swiss municipalities. European Journal of Epidemiology, 2016, 31, 763-774.	2.5	1
51	Pencil Beam Scanning Proton Therapy for Pediatric Parameningeal Rhabdomyosarcomas: Clinical Outcome of Patients Treated at the Paul Scherrer Institute. Pediatric Blood and Cancer, 2016, 63, 1731-1736.	0.8	34
52	Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000). Blood, 2016, 128, 4-4.	0.6	6
53	Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Oncotarget, 2016, 7, 1451-1463.	0.8	48
54	Parents' and patients' experiences with paediatric oncology care in Switzerland – satisfaction and some hurdles. Swiss Medical Weekly, 2016, 146, w14309.	0.8	15

#	Article	IF	CITATIONS
55	Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma. Pediatric Blood and Cancer, 2015, 62, 16-23.	0.8	26
56	Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors. Cancer Cell, 2015, 27, 298-311.	7.7	248
57	Decision-making capacity of children and adolescentsâ€"suggestions for advancing the concept's implementation in pediatric healthcare. European Journal of Pediatrics, 2015, 174, 775-782.	1.3	57
58	Genomics and drug profiling of fatal TCF3-HLFâ^'positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nature Genetics, 2015, 47, 1020-1029.	9.4	190
59	Background Ionizing Radiation and the Risk of Childhood Cancer: A Census-Based Nationwide Cohort Study. Environmental Health Perspectives, 2015, 123, 622-628.	2.8	107
60	Nonâ€anaplastic peripheral Tâ€cell lymphoma in children and adolescents – a retrospective analysis of the <scp>NHL</scp> â€ <scp>BFM</scp> study group. British Journal of Haematology, 2015, 168, 835-844.	1.2	42
61	Population mixing and the risk of childhood leukaemia in Switzerland: a census-based cohort study. European Journal of Epidemiology, 2015, 30, 1287-1298.	2.5	9
62	PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1. Oncotarget, 2015, 6, 28895-28910.	0.8	21
63	Pretreatment for Bilateral Nephroblastomatosis is an Independent Risk Factor for Progressive Disease in Patients with Stage V Nephroblastoma. Klinische Padiatrie, 2014, 226, 175-181.	0.2	29
64	FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells. International Journal of Cancer, 2014, 135, 1543-1552.	2.3	21
65	Malignant rhabdoid tumor of the kidney: significantly improved response to pre-operative treatment intensified with doxorubicin. Cancer Genetics, 2014, 207, 434-436.	0.2	14
66	A Prospective Multicenter Study of Microbiologically Defined Infections in Pediatric Cancer Patients With Fever and Neutropenia. Pediatric Infectious Disease Journal, 2014, 33, e219-e225.	1.1	32
67	Mental health-care utilization in survivors of childhood cancer and siblings: the Swiss childhood cancer survivor study. Supportive Care in Cancer, 2014, 22, 339-349.	1.0	20
68	Treatment and Outcome of Patients Suffering From Perineal/Perianal Rhabdomyosarcoma. Annals of Surgery, 2014, 259, 1166-1172.	2.1	27
69	Relapsed or Refractory Burkitt Lymphoma in Children and Adolescents after BFM-Type First-Line Therapy - a BFM Group Report. Blood, 2014, 124, 1738-1738.	0.6	2
70	Exploring the Association of Hemoglobin Level and Adverse Events in Children with Cancer Presenting with Fever in Neutropenia. PLoS ONE, 2014, 9, e101696.	1.1	7
71	Invasive Fungal Infections in Pediatric Acute Lymphoblastic Leukemia: Incidence, Characterization, Outcome and Risk Analysis of Study ALL-BFM 2000. Blood, 2014, 124, 3658-3658.	0.6	0
72	Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "watch and wait―strategy after complete resection. Annals of Hematology, 2013, 92, 1537-1541.	0.8	65

#	Article	IF	Citations
73	Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group. Journal of Clinical Oncology, 2013, 31, 2736-2742.	0.8	149
74	Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood, 2013, 121, 3153-3160.	0.6	105
75	Port-A-Cath–Related Thrombosis and Postthrombotic Syndrome in Pediatric Oncology Patients. Journal of Pediatrics, 2013, 163, 1340-1346.	0.9	40
76	Prediction of Outcome by Early Response in Childhood Acute Lymphoblastic Leukemia. Klinische Padiatrie, 2013, 225, S50-S56.	0.2	10
77	Key Treatment Questions in Childhood Acute Lymphoblastic Leukemia: Results in 5 Consecutive Trials Performed by the ALL-BFM Study Group From 1981 to 2000. Klinische Padiatrie, 2013, 225, S62-S72.	0.2	36
78	Serum Concentrations of Mannan-Binding Lectin (MBL) and MBL-Associated Serine Protease-2 and the Risk of Adverse Events in Pediatric Patients With Cancer and Fever in Neutropenia. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 155-161.	0.6	3
79	Treatment of Children and Adolescents With Hodgkin Lymphoma Without Radiotherapy for Patients in Complete Remission After Chemotherapy: Final Results of the Multinational Trial GPOH-HD95. Journal of Clinical Oncology, 2013, 31, 1562-1568.	0.8	127
80	Different fever definitions and the rate of fever and neutropenia diagnosed in children with cancer: A retrospective twoâ€center cohort study. Pediatric Blood and Cancer, 2013, 60, 799-805.	0.8	21
81	Cohort Profile: The Swiss Childhood Cancer Survivor Study. International Journal of Epidemiology, 2012, 41, 1553-1564.	0.9	128
82	Lineage Specification of Parietal Epithelial Cells Requires $\hat{l}^2$ -Catenin/Wnt Signaling. Journal of the American Society of Nephrology: JASN, 2012, 23, 63-72.	3.0	66
83	Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica, 2012, 97, 1048-1056.	1.7	57
84	Serious medical complications in children with cancer and fever in chemotherapyâ€induced neutropenia: Results of the prospective multicenter SPOG 2003 FN study. Pediatric Blood and Cancer, 2012, 59, 90-95.	0.8	17
85	Firstâ∈day stepâ∈down to oral outpatient treatment versus continued standard treatment in children with cancer and lowâ∈risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatric Blood and Cancer, 2012, 59, 423-430.	0.8	36
86	Smallâ€molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma. International Journal of Cancer, 2012, 131, 2153-2164.	2.3	65
87	Health-Related Quality of Life in Long-Term Survivors of Relapsed Childhood Acute Lymphoblastic Leukemia. PLoS ONE, 2012, 7, e38015.	1.1	36
88	Follow-up care amongst long-term childhood cancer survivors: A report from the Swiss Childhood Cancer Survivor Study. European Journal of Cancer, 2011, 47, 221-229.	1.3	42
89	Antibody levels against tetanus and diphtheria after polychemotherapy for childhood sarcoma: A report from the Late Effects Surveillance System. Vaccine, 2011, 29, 1565-1568.	1.7	12
90	CD133 Positive Embryonal Rhabdomyosarcoma Stem-Like Cell Population Is Enriched in Rhabdospheres. PLoS ONE, 2011, 6, e19506.	1.1	111

#	Article	lF	CITATIONS
91	Predicting Bacteremia in Children With Cancer and Fever in Chemotherapy-induced Neutropenia. Pediatric Infectious Disease Journal, 2011, 30, e114-e119.	1.1	60
92	Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood, 2011, 118, 1854-1864.	0.6	73
93	Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia, 2011, 25, 153-160.	3.3	86
94	Generation of a novel <i>rtTA</i> transgenic mouse to induce timeâ€controlled, tissueâ€specific alterations in <i>Pax2</i> à€expressing cells. Genesis, 2011, 49, 797-802.	0.8	6
95	Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element "Phase IB― A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000. Blood, 2011, 118, 1504-1504.	0.6	5
96	Mannan-binding lectin (MBL) and MBL-associated serine protease-2 in children with cancer. Swiss Medical Weekly, 2011, 141, w13191.	0.8	19
97	Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90. Journal of Clinical Oncology, 2010, 28, 2339-2347.	0.8	265
98	Access to specialized pediatric cancer care in Switzerland. Pediatric Blood and Cancer, 2010, 54, 721-727.	0.8	11
99	Prognostic relevance of dic(9;20)(p11;q13) in childhood Bâ€cell precursor acute lymphoblastic leukaemia treated with Berlinâ€Frankfurtâ€Münster (BFM) protocols containing an intensive induction and postâ€induction consolidation therapy. British Journal of Haematology, 2010, 149, 93-100.	1.2	18
100	p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. Oncogene, 2010, 29, 3942-3952.	2.6	29
101	Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia, 2010, 24, 265-284.	3.3	431
102	Family Characteristics as Risk Factors for Childhood Acute Lymphoblastic Leukemia: A Population-Based Case-Control Study. PLoS ONE, 2010, 5, e13156.	1.1	9
103	Predicting Adverse Events in Children With Fever and Chemotherapy-Induced Neutropenia: The Prospective Multicenter SPOG 2003 FN Study. Journal of Clinical Oncology, 2010, 28, 2008-2014.	0.8	140
104	Nuclear Accumulation of $\hat{l}^2$ -Catenin Protein Indicates Activation of wnt Signaling in Chemically Induced Rat Nephroblastomas. Pediatric and Developmental Pathology, 2010, 13, 1-8.	0.5	17
105	Immunity Against Tetanus and Diphtheria After Childhood Sarcoma Treatment. Klinische Padiatrie, 2010, 222, 196-196.	0.2	2
106	Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood, 2010, 115, 3206-3214.	0.6	685
107	Multidisciplinary management of childhood sarcoma: time to expand. Expert Review of Anticancer Therapy, 2010, 10, 1163-1166.	1.1	0
108	Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. Journal of Clinical Investigation, 2010, 120, 1310-1323.	3.9	287

#	Article	lF	CITATIONS
109	Furin Targeted Drug Delivery for Treatment of Rhabdomyosarcoma in a Mouse Model. PLoS ONE, 2010, 5, e10445.	1.1	31
110	Heterogeneity of the MYCN Oncogene in Neuroblastoma. Clinical Cancer Research, 2009, 15, 2085-2090.	3.2	52
111	Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2009, 189, 29-36.	1.0	5
112	Identification of a rhabdomyosarcoma targeting peptide by phage display with sequence similarities to the tumour lymphaticâ€homing peptide LyPâ€1. International Journal of Cancer, 2009, 124, 2026-2032.	2.3	28
113	Prognosis in pediatric hematologic malignancies is associated with serum concentration of mannoseâ€binding lectinâ€associated serine proteaseâ€2 (MASPâ€2). Pediatric Blood and Cancer, 2009, 53, 53-5	59.8 7.	21
114	Cytogenetic characterization of childhood acute lymphoblastic leukemia in Nicaragua. Pediatric Blood and Cancer, 2009, 53, 1238-1241.	0.8	12
115	Immunohistochemical detection of EGFR, fibrillinâ€2, Pâ€cadherin and AP2β as biomarkers for rhabdomyosarcoma diagnostics. Histopathology, 2009, 54, 873-879.	1.6	40
116	The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/ $\hat{l}^2$ -catenin pathway. Oncogene, 2009, 28, 2245-2256.	2.6	163
117	Leukemia-Initiating Cells Are Frequent in Very High Risk Childhood Acute Lymphoblastic Leukemia and Give Rise to Relatively Stable Phenotypes in Immunodeficient Mice Blood, 2009, 114, 86-86.	0.6	2
118	A psychoeducational intervention reduces the need for anesthesia during radiotherapy for young childhood cancer patients. Radiation Oncology, 2008, 3, 17.	1.2	35
119	SKY reveals a high frequency of unbalanced translocations involving chromosome 6 in t(12;21)-positive acute lymphoblastic leukemia. Leukemia Research, 2008, 32, 39-43.	0.4	11
120	Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia, 2008, 22, 771-782.	3.3	339
121	An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nature Medicine, 2008, 14, 979-984.	15.2	253
122	Karyotypic characterization of infant embryonal rhabdomyosarcoma. Cancer Genetics and Cytogenetics, 2008, 180, 145-148.	1.0	0
123	Phosphorylation Regulates Transcriptional Activity of PAX3/FKHR and Reveals Novel Therapeutic Possibilities. Cancer Research, 2008, 68, 3767-3776.	0.4	49
124	Initial Patient Characteristics Can Predict Pattern and Risk of Relapse in Localized Rhabdomyosarcoma. Journal of Clinical Oncology, 2008, 26, 406-413.	0.8	101
125	Anemia and survival in childhood acute lymphoblastic leukemia. Haematologica, 2008, 93, 1652-1657.	1.7	14
126	Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood, 2008, 111, 4477-4489.	0.6	511

#	Article	IF	Citations
127	Conservative Management of Acute Appendicitis in Children With Hematologic Malignancies During Chemotherapy-induced Neutropenia. Journal of Pediatric Hematology/Oncology, 2008, 30, 464-467.	0.3	39
128	Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL) Tj ETQq0 C	0 o r <b>g</b> BaT /O	verkook 10 Tf
129	Prevalence, Clinical Pattern, and Outcome of CNS Involvement in Childhood and Adolescent Non-Hodgkin's Lymphoma Differ by Non-Hodgkin's Lymphoma Subtype: A Berlin-Frankfurt-Mýnster Group Report. Journal of Clinical Oncology, 2007, 25, 3915-3922.	0.8	99
130	Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood, 2007, 110, 2084-2091.	0.6	53
131	Characterization of high-hyperdiploidy in childhood acute lymphoblastic leukemia with gain of a single chromosome 21. Leukemia and Lymphoma, 2007, 48, 2457-2460.	0.6	2
132	Loss of i(8)(q10) at relapse in two cases of childhood acute myeloid leukaemia. Leukemia and Lymphoma, 2007, 48, $1045-1047$ .	0.6	1
133	Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute. International Journal of Radiation Oncology Biology Physics, 2007, 67, 497-504.	0.4	75
134	Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene, 2007, 26, 7267-7281.	2.6	84
135	Immune activation suppresses initiation of lytic Epstein-Barr virus infection. Cellular Microbiology, 2007, 9, 2055-2069.	1.1	30
136	Clinical characteristics and treatment outcome of infants with non-Hodgkin lymphoma. British Journal of Haematology, 2007, 139, 070916051811006-???.	1.2	26
137	Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors. Cancer Genetics and Cytogenetics, 2007, 172, 61-65.	1.0	23
138	The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG). European Journal of Haematology, 2007, 78, 468-476.	1.1	39
139	Real-time broad-range PCR versus blood culture. A prospective pilot study in pediatric cancer patients with fever and neutropenia. Supportive Care in Cancer, 2007, 15, 637-641.	1.0	12
140	Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000 Blood, 2007, 110, 1425-1425.	0.6	2
141	Quantitative profiling of housekeeping and Epstein-Barr virus gene transcription in Burkitt lymphoma cell lines using an oligonucleotide microarray. Virology Journal, 2006, 3, 43.	1.4	30
142	Health-related quality of life in children with newly diagnosed cancer: a one year follow-up study. Health and Quality of Life Outcomes, 2006, 4, 63.	1.0	110
143	A t(12;17)(p13;q12) identifies a distinct TEL rearrangement-negative subtype of precursor-B acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2006, 165, 64-69.	1.0	13
144	Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma. Cancer Genetics and Cytogenetics, 2006, 167, 51-56.	1.0	33

#	Article	IF	CITATIONS
145	Cytogenetics of pineoblastoma: four new cases and a literature review. Cancer Genetics and Cytogenetics, 2006, 170, 175-179.	1.0	28
146	Subtype and Prognostic Classification of Rhabdomyosarcoma by Immunohistochemistry. Journal of Clinical Oncology, 2006, 24, 816-822.	0.8	133
147	Impact of Cranial Radiotherapy on Central Nervous System Prophylaxis in Children and Adolescents With Central Nervous System–Negative Stage III or IV Lymphoblastic Lymphoma. Journal of Clinical Oncology, 2006, 24, 491-499.	0.8	146
148	Superiority of Allogeneic Hematopoietic Stem-Cell Transplantation Compared With Chemotherapy Alone in High-Risk Childhood T-Cell Acute Lymphoblastic Leukemia: Results From ALL-BFM 90 and 95. Journal of Clinical Oncology, 2006, 24, 5742-5749.	0.8	118
149	Real-Time Quantitative Broad-Range PCR Assay for Detection of the 16S rRNA Gene Followed by Sequencing for Species Identification. Journal of Clinical Microbiology, 2006, 44, 2750-2759.	1.8	77
150	Clonal expansion of a new MLL rearrangement in the absence of leukemia. Blood, 2005, 105, 4151-4152.	0.6	20
151	The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. British Journal of Haematology, 2005, 131, 39-49.	1.2	278
152	Cytogenetic characterization of Ewing tumors with high-ploidy. Cancer Genetics and Cytogenetics, 2005, 159, 160-163.	1.0	6
153	Characterization of karyotypic events and evolution in neuroblastoma. Pediatric Blood and Cancer, 2005, 44, 147-157.	0.8	20
154	Gene Expression Signatures Identify Rhabdomyosarcoma Subtypes and Detect a Novel t(2;2)(q35;p23) Translocation Fusing PAX3 to NCOA1. Cancer Research, 2004, 64, 5539-5545.	0.4	224
155	Human tonsillar tissue block cultures differ from autologous tonsillar cell suspension cultures in lymphocyte subset activation and cytokine gene expression. Journal of Immunological Methods, 2004, 289, 179-190.	0.6	17
156	Aberrations involving $13q12\hat{a}^{1/4}q14$ are frequent secondary events in childhood acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2004, 151, 157-161.	1.0	9
157	Withholding initial vancomycin in febrile neutropenia despite implanted catheters. European Journal of Pediatrics, 2004, 163, 422-3.	1.3	4
158	Solitary infantile choriocarcinoma of the liver: MRI findings. Pediatric Radiology, 2004, 34, 820-823.	1.1	20
159	The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood, 2004, 105, 948-958.	0.6	304
160	Gene expression profiles and risk stratification in childhood acute lymphoblastic leukemia. Haematologica, 2004, 89, 801-8.	1.7	17
161	Burkitt's lymphoma with bilateral cavernous sinus and mediastinal involvement in a child. Pediatric Radiology, 2003, 33, 719-721.	1.1	36
162	Paraneoplastic syndromes in ganglioneuroblastoma: contrasting symptoms of constipation and diarrhoea. European Journal of Pediatrics, 2003, 162, 511-513.	1.3	21

#	Article	IF	CITATIONS
163	Quantitative cytokine gene expression in human tonsils at excision and during histoculture assessed by standardized and calibrated real-time PCR and novel data processing. Journal of Immunological Methods, 2003, 283, 27-43.	0.6	34
164	Abnormal constitutional karyotypes in patients with neuroblastoma: a report of four new cases and review of 47 others in the literature. Cancer Genetics and Cytogenetics, 2003, 147, 89-98.	1.0	45
165	Nuclear accumulation of ?-catenin protein in Wilms' tumours. Journal of Pathology, 2003, 199, 68-76.	2.1	66
166	Induction of Long-Term Remission of a Relapsed Childhood B–Acute Lymphoblastic Leukemia With Rituximab Chimeric Anti-CD20 Monoclonal Antibody and Autologous Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2003, 25, 327-329.	0.3	33
167	Interphase fluorescence in situ hybridization detection of chromosome 17 and 17q region gains in neuroblastoma. Cancer Genetics and Cytogenetics, 2002, 137, 95-101.	1.0	10
168	The Investigation of Karyotypic Instability in the High-Hyperdiploidy Subgroup of Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 2001, 42, 187-193.	0.6	9
169	Constitutional Balanced Chromosomal Rearrangements and Neoplasm in Children. The American Journal of Pediatric Hematology/oncology, 2001, 23, 582-584.	1.3	11
170	Detection of unidentified chromosome abnormalities in human neuroblastoma by spectral karyotyping (SKY). Genes Chromosomes and Cancer, 2001, 31, 201-208.	1.5	21
171	Loss of X chromosome in childhood acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2001, 125, 27-29.	1.0	14
172	Cloning and Characterization of the Human PAX7 Promoter. Biological Chemistry, 2000, 381, 331-5.	1.2	10
173	Trisomy 1q Generating Translocations in Wilms Tumor. Cancer Genetics and Cytogenetics, 1999, 112, 138-143.	1.0	12
174	Clustered organization of S100 genes in human and mouse. Biochimica Et Biophysica Acta - Molecular Cell Research, 1998, 1448, 254-263.	1.9	74
175	A Further Case of a $t(11;20)(p15;q11.2)$ Translocation in an Acute Myeloid Leukemia (FAB M2). Journal of Pediatric Hematology/Oncology, 1998, 20, 91-93.	0.3	5
176	Routine Karyotyping in Wilms Tumor. Cancer Genetics and Cytogenetics, 1997, 96, 151-156.	1.0	33
177	A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype., 1997, 28, 136-138.		27
178	Cytogenetic analysis in a case of intraocular medulloepithelioma. Cancer Genetics and Cytogenetics, 1996, 92, 144-146.	1.0	15
179	Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies. Oncology Reports, 1994, 20, 463.	1.2	11
180	Spectrum Of Peritoneal Mesothelioma In Childhood: Clinical And Histopathologic Features, Including Dna Cytometry. Pediatric Hematology and Oncology, 1994, 11, 399-408.	0.3	23

#	Article	IF	CITATIONS
181	Pre-operative radiotherapy is associated with superior local relapse-free survival in advanced synovial sarcoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	O